

109TH CONGRESS
1ST SESSION

H. R. 2574

To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research on animals to develop techniques for the derivation of stem cells from embryos that do not harm the embryos, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MAY 24, 2005

Mr. BARTLETT of Maryland (for himself, Mr. GINGREY, Mr. NORWOOD, Mr. OSBORNE, Mr. CULBERSON, Mr. ENGLISH of Pennsylvania, Mr. ROHRABACHER, Mr. PRICE of Georgia, and Mr. CANNON) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research on animals to develop techniques for the derivation of stem cells from embryos that do not harm the embryos, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Respect for Life Em-
5 bryonic Stem Cell Act of 2005”.

1 **SEC. 2. FINDINGS.**

2 The Congress finds as follows:

3 (1) The President’s Council on Bioethics in its
4 May 2005 White Paper: “Alternative Sources of
5 Pluripotent Stem Cells,” acknowledges that
6 pluripotent stem cell lines might be derived from an
7 early stage human embryo without harming the em-
8 bryo’s prospects for developing into a baby.

9 (2) Identical twinning occurs spontaneously in
10 nature during at least two stages of the in vivo
11 human development process demonstrating the via-
12 bility and feasibility of the removal of some cells
13 from an early stage human embryo without harming
14 the embryo’s ability to develop into a baby.

15 (3) The removal of some cells from living
16 human embryos is already occurring to conduct
17 preimplantation genetic diagnosis (“PGD”). PGD is
18 a procedure increasingly offered to individuals seek-
19 ing to become parents as an option in conjunction
20 with assisted reproductive technologies to diagnose
21 their embryos created through in vitro fertilization
22 (“IVF”) for genetic and chromosomal abnormalities
23 prior to implantation and pregnancy.

24 (4) There have been reports that more than
25 1,000 babies have been born worldwide and more

1 than 150 babies have been born in the United States
2 after undergoing PGD as early stage embryos.

3 (5) IVF to create and PGD to diagnose early
4 stage human embryos is proceeding without Federal
5 funding.

6 (6) There is no Federal prohibition against
7 using IVF to create or PGD to diagnose early stage
8 human embryos.

9 (7) Informed parental consent is obtained and
10 granted by individuals to utilize IVF and PGD on
11 behalf of themselves and to benefit their children.

12 (8) Cells removed for PGD from an early stage
13 human embryo might be cultured to produce and
14 store a stock of cells that could become a genetically
15 matched repair kit for that individual.

16 (9) Surplus cells from an individual's repair kit
17 might be used to establish an embryonic stem cell
18 line made available for basic and applied research to
19 develop treatments for debilitating and deadly
20 human ailments.

21 (10) Individuals seeking to become parents who
22 have already chosen and committed to use PGD and
23 establish a repair kit for the benefit of their children
24 could have the option to donate surplus cells from

1 their children’s repair kit for the establishment of a
2 new embryonic stem cell line.

3 **SEC. 3. DERIVATION OF STEM CELLS WITHOUT HARMING**
4 **EMBRYOS; ANIMAL RESEARCH THROUGH NA-**
5 **TIONAL INSTITUTES OF HEALTH.**

6 Part B of title IV of the Public Health Service Act
7 (42 U.S.C 284) is amended by adding at the end the fol-
8 lowing:

9 **“SEC. 409J. BASIC AND APPLIED RESEARCH ON DERIVA-**
10 **TION OF STEM CELLS WITHOUT HARMING**
11 **EMBRYOS.**

12 “(a) IN GENERAL.—With respect to producing stem
13 cell lines for research on treatments for diseases and other
14 adverse health conditions, the Director of NIH shall,
15 through the appropriate national research institutes, pro-
16 vide for the conduct and support of basic and applied re-
17 search—

18 “(1) to develop techniques for the derivation of
19 stem cells from embryos that do not harm the em-
20 bryos; and

21 “(2) in the case of stem cells that are derived
22 without harming the embryo, to develop techniques
23 for storing the stem cells for the possibility that in
24 the future a therapy may be developed that uses the

1 stem cells of an animal to adapt the therapy to that
2 particular animal.

3 “(b) PROHIBITIONS REGARDING CLINICAL RE-
4 SEARCH.—Research under subsection (a) may not include
5 clinical research, and may not include any research that—

6 “(1) involves the derivation of stem cells from
7 human embryos; or

8 “(2) uses any stem cell to create or to attempt
9 to create a human embryo.

10 “(c) AUTHORIZATION OF APPROPRIATIONS.—For the
11 purpose of carrying out this section, there is authorized
12 to be appropriated \$10,000,000 in the aggregate for the
13 fiscal years 2006 through 2010.”.

○